| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2849380 | American Heart Journal | 2014 | 11 Pages |
Abstract
Erythropoiesis-stimulating agent administration does not result in an increased risk of adverse cardiac events in STEMI patients undergoing primary PCI. Results of ongoing studies may provide further insight to the potential beneficial clinical effects of ESAs in STEMI patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marieke L. MD, PhD, Peter MD, PhD, Sunil V. MD, Anne M. MD, PhD, Maurizio MD, Hans L. PhD, Stuart D. MD, MS, Erik MD, PhD, Andrew J. MRCP, MD, Ilka MD, PhD, Fabrice MD, PhD, Dong-Ju MD, PhD, Ken MD, PhD, Dirk J. MD, PhD, Adriaan A. MD, PhD,